American Biomed Inc. signs agreements with U.S. Gov't. Dept. of Defense & Veterans Admin. Agencies.THE WOODLANDS, Texas--(BUSINESS WIRE)--Aug. 20, 1996--American BioMed Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:ABMI ABMI Autologous Bone Marrow Infusion ), of The Woodlands, Tuesday announced that it has signed a Distribution and Pricing Agreement (DAPA DAPA Diaminopimelic Acid DAPA Drug and Alcohol Program Advisor DAPA Diplomate of the American Psychotherapy Association DAPA Distribution And Pricing Agreement DAPA Defense Acquisition and Program Administration (South Korea) ) issued by the Defense Personnel Support Center and signed an extension to our Federal Supply Schedule (FSS FSS Federal Supply Service (US General Services Administration) FSS Flight Service Station FSS Family Self-Sufficiency FSS Fixed Satellite Service FSS Forensic Science Service (Great Britain) ) issued by the Department of Veterans Affairs. The DAPA agreement is effective from September 1996 to September 2000 and allows American BioMed to supply its current product line of embolectomy embolectomy /em·bo·lec·to·my/ (em?bo-lek´tah-me) surgical removal of an embolus. em·bo·lec·to·my n. Surgical removal of an embolus. embolectomy surgical removal of an embolus. , embolectomy/irrigation, occlusion, billiary, and thermodilution catheters to U.S. military hospitals. Distribution is through the Department of Defense Prime Vendor program. In 1996, to date, $71,000 in product sales have already occurred. The FSS agreement is now effective until Dec. 31, 1999 and allows the company to participate in the VA's Medical/Surgical Distribution Program. This agreement provides American BioMed with market access to all VA hospitals. Arthur S. Przybyl, VP of Sales and Marketing, stated: "These agreements are part of our continuing strategy to strengthen market visibility for our current product line and should contribute $200,000.00 in annual product sales. We continue to provide distribution channel flexibility to our customers, who can buy our products, directly or through specialty medical distributors or through specific medical/surgical distribution programs." American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually. The devices include but are not limited to the OmniCath(r) atherectomy catheter, as well as the company's nine patented FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved unique all-silicone balloon catheters. These consist of thermodilution, embolectomy and bi-lumen irrigation irrigation, in agriculture, artificial watering of the land. Although used chiefly in regions with annual rainfall of less than 20 in. (51 cm), it is also used in wetter areas to grow certain crops, e.g., rice. , urinary bladder and angioscopy catheters. The OmniStent(tm) and accompanying stent technology is used to support diseased blood vessels. Other devices such as the company's drug delivery catheters, guidewire microfilter and minimally invasive spinal instruments are also under development. CONTACT: Thomas E. Waite & Associates Inc. 407/324-1606 Fax 407/324-0664 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion